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multiple pregnancies?In the past issue of the Taiwanese Journal of Obstetrics and Gyne-
cology (Volume 52, Number 4, pages 470e474), a review article by
Shaw and colleagues [1] attracted our interest. The authors wrote a
very nice review article entitled “From Down syndrome screening
to noninvasive prenatal testing: 20 years' experience in Taiwan”,
and discussed the trends and changes in the use of noninvasive pre-
natal testing (NIPT) for Down screening test in Taiwan [1]. Themain
ﬁndings in 20 years in Taiwan include: (1) Down screening test
shifts to the ﬁrst trimester although the second trimester quadruple
test is still popular in Taiwan. (2) NIPT may be a promising
screening tool for fetal chromosome aneuploidies, and in addition,
the authors highlighted the value of NIPT (mainly indicating a cell-
free fetal DNA test); the authors suggested some indications to bal-
ance the cost and effectiveness if a cell-free fetal DNA test was
applied for pregnant women, as they agreed with the fact that
NIPT did not achieve a satisfactory level as the ﬁrst-line routine pre-
natal evaluation, because of poor medical cost-effectiveness [1].
However, the authors' suggestion needs further clariﬁcation.
The authors recommended that pregnant women, who are often
afraid of invasive amniocentesis, have already had early rupture of
membrane, multiple pregnancies, and good economic status, could
be clinical and practical indications for NIPT, based on the authors'
understanding of the recent committee opinion for NIPT for fetal
aneuploidy by the American College of Obstetricians and Gynecol-
ogists (ACOG; Committee Opinion No. 545: noninvasive prenatal
testing for fetal aneuploidy) [2]. We welcome the fact that the au-
thors could clearly demonstrate the suggestions, but one of these
indicationsdmultiple pregnanciesdseemed to be well under the
level that can convince physicians, because the value of NIPT for
prenatal diagnosis inmultiple pregnancies is still uncertain. Prelim-
inary data available on twins demonstrate accuracy in a very small
cohort [3], but the ACOG commented that a cell-free fetal DNA
result may be difﬁcult to obtain in a small percentage of cases [2].
Alternatively, the ACOG recommended that more data are neces-
sary to conﬁdentially apply NIPT in twin pregnancies [2], suggest-
ing that for twin pregnancies, the evidence might not be strong
enough. We believe that evidence of the use of a free fetal DNA
test for triple or quadrant pregnancies or higher might be well un-
der the level that supports value. Thus, wewonder why the authors
could suggest that NIPT could be indicated for multiple
pregnancies.
We would like to point out that the indications for considering
the use of cell-free fetal DNA according to the latest ACOG Commit-
tee opinions [3] are as follows: (1) maternal age 35 years or older at
delivery; (2) fetal ultrasound ﬁndings indicating an increased risk
of aneuploidy; (3) history of a prior pregnancy with a trisomy; (4)http://dx.doi.org/10.1016/j.tjog.2014.02.002
1028-4559/Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Publishedpositive test result for aneuploidy, including ﬁrst trimester, sequen-
tial, or integrated screen, or quadruple screen; and (5) parental
balanced robertsonian translocation with increased risk of fetal tri-
somy 13 or trisomy 21. In fact, all of these indications are well
known for the indications for amniocentesis in clinical practice
[4e6].
Nevertheless, we congratulate Dr Shaw and colleagues [1] for
their publication, because their excellent review provided the latest
knowledge and research evidence on NIPT for prenatal diagnoses.
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